We found that clones expressing the dominant negative form of the PKR gene were not only resistant to IFN-$gamma$-mediated killing, but were also incapable of inducing accumulation of IDO protein after IFN-$gamma$ treatment.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:We investigated whether the activity of double-stranded RNA activated kinase (p68/PKR) is necessary for induction of IDO (indolamine 2,3 -dioxygenase) gene by IFN-$gamma$.
📊
Key Findings & Data:Clones of ME180 cells expressing the dominant negative form of PKR were selected in the presence of neomycin.
💡
Conclusion & Impact:We found that clones expressing the dominant negative form of the PKR gene were not only resistant to IFN-$gamma$-mediated killing, but were also incapable of inducing accumulation of IDO protein after IFN-$gamma$ treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
We investigated whether the activity of double-stranded RNA activated kinase (p68/PKR) is necessary for induction of IDO (indolamine 2,3 -dioxygenase) gene by IFN-$gamma$. For this purpose, we planned to abrogate the function of cellular wt-PKR gene. Clones of ME180 cells expressing the dominant negative form of PKR were selected in the presence of neomycin. Then these cells were treated with IFN-$gamma$ and accumulation of IDO protein was determined by Western blot analysis. We found that clones expressing the dominant negative form of the PKR gene were not only resistant to IFN-$gamma$-mediated killing, but were also incapable of inducing accumulation of IDO protein after IFN-$gamma$ treatment.
🔖
Cite This Article
İMİR, N. G., ÖZEŞ, O. N., GELEN, T., ÖĞÜŞ, M., KARAVELİ, S., NASIRCILAR, A. G., AKÇA, H. (2022). IFN-gamma-mediated transcriptional induction of the IDO (Indolamine 2,3-dioxygenase) gene requires activity of p68/PKR protein kinase. Turkish Journal of Medical Sciences, Cilt: 32 - Sayı: 3, 195–199. https://ajindex.com/articles/612230
Baron S, Copenhaver DH, Dianzani F, Fleishmann WR, Hughes TK, Klimpel GR, Nielse DW, Stanton GJ and Tyring SK. Interferon. Principles and Medical Applications, 212-213, 1992
Isaacs A, and Lindenmann, J. Virus interference. I. The interferon. Proc R Soc. London Ser. B 147: 258-267, 1957
Branca A and Baglioni C. Evidence that type I and type II IFNs have different receptors. Nature 294: 768-70, 1981
Bach EA, Aguet M, and Schrebier RD. The interferon gamma receptor: a paradigm for cytokine receptor signaling. Ann Rev Immunol 15: 563-591, 1997
Mogensen KE, Lewerenz M, Reboul J, Lutfalla G and Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J. Interferon. Cytokine Res. 19: 1069-1098, 1999
Nguyen H, Hiscott J, and Pitha PM. The growing family interferon regulatory factors. Cytokine Growth Factor Rev. 8: 293-312, 1997
Stark GR, Kerr IM, Williams BR, Silverman RH and Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 67: 227-264, 1998
Chang CH, Hammer J, Loh JE, Fodor WL and Flavell RA. The activation of major histocompability complex I genes by interferon regulated factor 1 (IRF-1). Immunogenetics 35: 378-84, 1992
Loh JE, Chang CH, Fodor WL and Flavell RA. Dissection of the interferon gamma- MHC class II signal transduction pathway reveals that type I and type II interferon system share common signaling components. EMBO J 11: 1351-63, 1992
Özeş ON and Taylor MW. Reversal of IFN-gamma-resistant phenotype by poly I: C. Possible involvement of doublestranded RNA-activated kinase in IFNgamma signaling. J of Interferon Res 13: 283-88, 1993
Clemens MJ, Elia A. The double-stranded RNA dependent protein kinase PKR: structure and function. J Interferon Cytokine Res. 17: 503-524, 1997
Thomis DC, Doohan JD, and Samuel CE. Mechanism of interferon action: cDNA structure, expression and regulation of the interferon-induced, RNA dependent PI/eIF2-_ protein kinase from human cells. Virology. 188: 33-46, 1992
Jeffrey IW, Kadereit S, Meurs EF, Metzger T, Bachman M, Cshwemmle M, Hovanessian AG and Clemens MJ. Nuclear localization of the interferoninducible protein kinase PKR in human cells and transfected mouse cells. Experimental Cell Research 218: 17- 27, 1995
Samuel CE. Antiviral action of interferons. Clinical Microbiological Rev. Vol 14. No 4: 778-809, 2001
Samuel CE. Mechanism of interferon action. Phosphorylation of protein synthesis initiation fact